Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | FNTA | P49354 | 7/20 | 0.46 |
| ▸ | FNTB | P49356 | 7/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7513048 | 1.00 | MAPK1 (0.48) | MAPK1CYP11B1CYP11B2NPC1FNTA | |
| SCHEMBL5298259 | 0.93 | FNTA (0.51) | MAPK1CYP11B1CYP11B2FNTAFNTB | |
| SCHEMBL8434426 | 0.93 | FNTA (0.51) | MAPK1CYP11B1CYP11B2FNTAFNTB | |
| SCHEMBL8436859 | 0.91 | FNTA (0.55) | MAPK1CYP11B1CYP11B2NPC1FNTA | |
| SCHEMBL6003187 | 0.91 | FNTA (0.55) | MAPK1CYP11B1CYP11B2NPC1FNTA | |
| SCHEMBL8534851 | 0.88 | CYP11B1 (0.53) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL8097870 | 0.88 | CYP11B1 (0.53) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL8098295 | 0.87 | FNTA (0.49) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL8442897 | 0.87 | FNTA (0.49) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL8104389 | 0.85 | ALDH1A1 (0.57) | CYP11B1CYP11B2FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1019529-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2002-09-11 | — | — | EP | claimed |
| JP-2001518281-A | — | — | 2001-10-16 | — | — | JP | claimed |
| EP-1019529-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| EP-1019530-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| EP-1009854-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-06-21 | — | — | EP | claimed |
| WO-1999010525-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1999010524-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1999010523-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | claimed |
| EP-1866285-A1 | 1-SULFONYL-PIPERDINE-3-CARBOXYLIC ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS | F. Hoffmann-Roche AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006094633-A1 | 1- SULFONYL-PI PERDINE- 3 -CARBOXYL I C ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199816-A1 | Aryl sulfonyl piperidines | GILLESPIE PAUL | 2006-09-07 | — | — | US | disclosed |
| EP-1019529-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2002-09-11 | — | — | EP | disclosed |
| US-6127366-A | ANTICARCINOGENIC OR ANTITUMOR AGENTS | MERCK & CO., INC. (US) | 2000-10-03 | — | — | US | disclosed |
| US-6103487-A | DETECTING MODULATORS THAT SUPPRESS THE ACTIVITY OF A TRANSFERASES; ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 2000-08-15 | — | — | US | disclosed |
| WO-1999010524-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999010525-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0862435-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-02-03 | — | — | EP | disclosed |
| US-5817678-A | IMIDAZOLE-CONTAINING PIPERIDINE DERIVATIVES, PEPTIDEMIMETIC | MERCK & CO., INC. (US) | 1998-10-06 | — | — | US | disclosed |
| EP-0862435-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997018813-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199816-A1 | Aryl sulfonyl piperidines | GPR119, SLC5A2, GLS2 | MAPK1 2294/4885CYP11B1 270/4885CYP11B2 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.